Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of subcutaneous zalunfiban in pre-hospital STEMI
2023-508485-15-00Phase 3Completed
- Sponsor
- CeleCor Therapeutics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Zalunfiban arm with Placebo arm (2 arms). Primary endpoints: Composite clinical outcome ranked on a 7-point scale at 30 days and Major bleeding events by GUSTO criteria at 30 days. Started Dec 2023; status: completed.
02
Drugs
zalunfiban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2023-508485-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508485-15-00.